Who was enrolled in STRIDE?

People with symptomatic peripheral artery disease and type 2 diabetes. The diabetes criterion is in the published title and is often dropped in summaries.

Why measure walking capacity?

Claudication — pain limiting walking distance — is the defining symptom, so it tests what the condition actually does rather than a surrogate.

What did the subgroup analysis show?

Rasouli 2025 examined benefit by baseline diabetes characteristics. Subgroup analyses within a trial are hypothesis-generating rather than definitive.

Research & Regulatory News

STRIDE and the Qualifier That Keeps Getting Dropped

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Bonaca and colleagues published STRIDE in the Lancet in May 2025: a phase 3b, double-blind randomised trial of semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes.

Key facts

Trial: STRIDE
Published: Lancet, 3 May 2025 (PMID 40169145)
Design: Phase 3b, double-blind, randomised
Population: Symptomatic PAD and type 2 diabetes
Endpoint: Walking capacity
Subgroup analysis: Rasouli 2025 (PMID 40543068)

The qualifier in the title

The trial enrolled people with symptomatic peripheral artery disease AND type 2 diabetes. That second criterion appears in the published title and is routinely dropped when the result is summarised as semaglutide improving walking in peripheral artery disease. It defines who the finding applies to, and dropping it widens the claim beyond what was studied.

Why walking capacity is the right endpoint

The defining symptom of peripheral artery disease is claudication — pain on walking that limits how far a person can go. Measuring walking distance tests the thing the condition actually does to people, rather than a surrogate such as an imaging measure or an ankle pressure index. It is a functional endpoint, which is generally harder to move and more meaningful when it does move.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

Why a functional endpoint is unusual in this literature

Most incretin trials report weight, glycaemic measures or event counts. A trial whose primary question is how far someone can walk is asking about capability rather than biology, and that connects to the body composition discussion elsewhere on this site — functional measures test whether a change in composition or physiology matters to what a person can do.

What the subgroup analysis examined

Rasouli and colleagues published on benefit by baseline type 2 diabetes characteristics in Diabetes Care in September 2025. Subgroup analyses within a randomised trial examine whether an effect is consistent across the enrolled population, and they are hypothesis-generating rather than definitive because the trial was not randomised within subgroups.

What this adds to the indication picture

Cardiovascular events in SELECT, kidney events in FLOW, liver histology in ESSENCE, heart failure in STEP-HFpEF and now walking capacity in peripheral artery disease. The pattern across these is a metabolic agent being assessed organ system by organ system, and reported as under regulatory review for indications beyond weight.

The boundary

Semaglutide is a licensed medicine and STRIDE was a registered randomised trial conducted under clinical supervision. Nothing supplied on this site is semaglutide or is an alternative to any treatment for peripheral artery disease.

Extended research context

The Research & Regulatory News deep dive

Deep dive: why 2026 was the year the incretin field split in two

For a decade every meaningful GLP-1 medicine was a peptide, and every one of them was injected. 2026 broke that pattern in both directions at once. In August the MHRA authorised orforglipron, a small molecule with no peptide bonds that works as an ordinary daily tablet. Three months earlier, retatrutide's TRIUMPH-1 reported a 28.3% mean weight reduction — the largest figure yet from a single molecule, and achievable only with a peptide capable of engaging three receptors at once. The field is not converging on one answer; it is separating into a convenience track and a magnitude track, and those tracks have different chemistry.

Deep dive: what a marketing authorisation actually means

An authorisation is granted to a specific product, in a specific formulation, for a specific indication, by a specific regulator. It is not a statement about a compound class and it does not transfer. Orforglipron being licensed in the UK tells you nothing about the legal or regulatory status of any other incretin, and nothing at all about compounds that remain investigational. Authorisation is also separate from funding: a licensed medicine is not automatically available on the NHS, which requires a further NICE appraisal.

Deep dive: reading trial results without being misled

Headline percentages are the least transferable part of a trial. A figure is only meaningful alongside its population, its duration, its comparator and its dropout rate. TRIUMPH-1's 28.3% came from an 80-week study in a relatively uncomplicated obesity population; TRIUMPH-3's 22.6% came from adults with severe obesity and established cardiovascular disease, and the gap between those two numbers is mostly population, not potency. Discontinuation rates deserve the same attention as efficacy: 11.3% of the TRIUMPH-1 12 mg arm stopped due to adverse events against 4.9% on placebo, and that figure is routinely dropped from summaries.

Research applications

▸Tracking regulatory status of investigational incretin compounds
▸Understanding the difference between authorisation, NICE appraisal and NHS availability
▸Comparing peptide and non-peptide receptor agonist pharmacology
▸Interpreting Phase 3 topline releases before peer-reviewed publication
▸Verifying trial identity against ClinicalTrials.gov registrations

Handling checklist

✓Check the compound named in a trial registration matches the compound being discussed
✓Confirm the NCT identifier resolves to the acronym being cited
✓Read topline press releases as preliminary until peer-reviewed publication
✓Separate the trial population from the headline percentage before comparing studies
✓Treat authorisation in one jurisdiction as saying nothing about status in another

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Treating a positive Phase 3 as approval

Fix: Filing begins a review that commonly takes a year or more and can end in a request for more data.

✗ Comparing weight-reduction percentages across different trials

Fix: Population, duration and comparator differ; the numbers are not interchangeable.

✗ Assuming one incretin's approval legitimises another compound

Fix: Authorisations are product-specific and do not transfer between compounds.

✗ Citing a TRIUMPH number without checking the NCT identifier

Fix: Verify against ClinicalTrials.gov — the numbering has been widely misreported.

✗ Reading research material as an alternative to a licensed medicine

Fix: Research material is supplied for laboratory use only and is not a substitute for anything prescribed.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Who was enrolled in STRIDE?: People with symptomatic peripheral artery disease and type 2 diabetes. The diabetes criterion is in the published title and is often dropped in summaries.
Why measure walking capacity?: Claudication — pain limiting walking distance — is the defining symptom, so it tests what the condition actually does rather than a surrogate.
What did the subgroup analysis show?: Rasouli 2025 examined benefit by baseline diabetes characteristics. Subgroup analyses within a trial are hypothesis-generating rather than definitive.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Research & Regulatory News articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum